Literature DB >> 31830341

Inherited salt-losing tubulopathy: An old condition but a new category of tubulopathy.

Kandai Nozu1, Tomohiko Yamamura1, Tomoko Horinouchi1, China Nagano1, Nana Sakakibara1, Kenji Ishikura2, Riku Hamada3, Naoya Morisada1, Kazumoto Iijima1.   

Abstract

Bartter syndrome (BS) and Gitelman syndrome (GS) are syndromes associated with congenital tubular dysfunction, characterized by hypokalemia and metabolic alkalosis. Clinically, BS is classified into two types: the severe antenatal/neonatal type, which develops during the fetal period with polyhydramnios and preterm delivery; and the relatively mild classic type, which is usually found during infancy with failure to thrive. GS can be clinically differentiated from BS by its age at onset, usually after school age, or laboratory findings of hypomagnesemia and hypocalciuria. Recent advances in molecular biology have shown that these diseases can be genetically classified into type 1 to 5 BS and GS. As a result, it has become clear that the clinical classification of antenatal/neonatal BS, classic BS, and GS does not always correspond to the clinical symptoms associated with the genotypes in a one-to-one manner; and there is clinically no clear differential border between type 3 BS and GS. This has caused confusion among clinicians in the diagnosis of these diseases. It has been proposed that the disease name "inherited salt-losing tubulopathy" can be used for cases of tubulopathies accompanied by hypokalemia and metabolic alkalosis. It is reasonable to use this term prior to genetic typing into type 1-5 BS or GS, to avoid confusion in a clinical setting. In this article, we review causative genes and phenotypic correlations, diagnosis, and treatment strategies for salt-losing tubulopathy as well as the clinical characteristics of pseudo-BS/GS, which can also be called a "salt-losing disorder".
© 2019 Japan Pediatric Society.

Entities:  

Keywords:  zzm321990HNF1Bzzm321990; Bartter syndrome; CASR; Gitelman syndrome; congenital chloride diarrhea; pseudo-Bartter syndrome; pseudo-Gitelman syndrome

Mesh:

Substances:

Year:  2020        PMID: 31830341     DOI: 10.1111/ped.14089

Source DB:  PubMed          Journal:  Pediatr Int        ISSN: 1328-8067            Impact factor:   1.524


  6 in total

1.  The Bartter-Gitelman Spectrum: 50-Year Follow-up With Revision of Diagnosis After Whole-Genome Sequencing.

Authors:  Mark Stevenson; Alistair T Pagnamenta; Heather G Mack; Judith Savige; Edoardo Giacopuzzi; Kate E Lines; Jenny C Taylor; Rajesh V Thakker
Journal:  J Endocr Soc       Date:  2022-05-15

Review 2.  Molecular Basis, Diagnostic Challenges and Therapeutic Approaches of Bartter and Gitelman Syndromes: A Primer for Clinicians.

Authors:  Laura Nuñez-Gonzalez; Noa Carrera; Miguel A Garcia-Gonzalez
Journal:  Int J Mol Sci       Date:  2021-10-22       Impact factor: 5.923

3.  Contradiction between genetic analysis and diuretic loading test in type I Bartter syndrome: a case report.

Authors:  Jumpei Kuroda; Ryoko Harada; Riku Hamada; Yusuke Okuda; Yasuhiro Yoshida; Hiroshi Hataya; Kandai Nozu; Kazumoto Iijima; Masataka Honda; Kenji Ishikura
Journal:  BMC Nephrol       Date:  2021-08-30       Impact factor: 2.388

4.  Urinary Extracellular Vesicles and Salt-Losing Tubulopathies: A Proteomic Approach.

Authors:  Francesca Raimondo; Clizia Chinello; Luigi Porcaro; Fulvio Magni; Marina Pitto
Journal:  Proteomes       Date:  2020-05-09

5.  Bartter syndrome with long-term follow-up: a case report.

Authors:  Xueling Wu; Gang Yang; Shiyu Chen; Min Tang; Shan Jian; Fuhui Chen; Xiulin Wu
Journal:  J Int Med Res       Date:  2020-08       Impact factor: 1.671

6.  Examination of the predicted prevalence of Gitelman syndrome by ethnicity based on genome databases.

Authors:  Atsushi Kondo; China Nagano; Shinya Ishiko; Takashi Omori; Yuya Aoto; Rini Rossanti; Nana Sakakibara; Tomoko Horinouchi; Tomohiko Yamamura; Sadayuki Nagai; Eri Okada; Yuko Shima; Koichi Nakanishi; Takeshi Ninchoji; Hiroshi Kaito; Hiroki Takeda; Hiroaki Nagase; Naoya Morisada; Kazumoto Iijima; Kandai Nozu
Journal:  Sci Rep       Date:  2021-08-09       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.